Lesson
Aqueous Humor, Intraocular Pressure, and Optic Nerve Risk
Glaucoma is progressive optic neuropathy. Intraocular pressure is the major modifiable risk factor, but damage depends on susceptibility, baseline structure, visual function, pressure pattern, and time.
- Anterior segment flow
- Trabecular and uveoscleral outflow
- Optic disc cupping
- Optic nerve progression
Posterior chamber secretion
Iris configuration can obstruct flow
Two outflow pathways
Structure and function define progression
Follow aqueous humor flow
The ciliary processes produce aqueous humor, which moves through the pupil into the anterior chamber. It exits mainly through the trabecular meshwork and Schlemm canal, with an additional uveoscleral pathway through ciliary muscle spaces.
Keep aqueous and vitreous compartments distinct
Aqueous humor is continuously produced and drained in the anterior segment. Vitreous humor is the gelatinous material behind the lens and is not the fluid that normally cycles through the trabecular meshwork. This distinction prevents incorrect mechanism maps and explains why angle anatomy is central to aqueous outflow disease.
Separate open and closed angle mechanisms
Open-angle disease has an anatomically accessible angle with impaired outflow or optic nerve vulnerability. Angle closure involves mechanical obstruction of the drainage angle and may become an emergency. A pressure-lowering medicine does not replace definitive angle evaluation.
Recognize normal-pressure disease
Normal-tension glaucoma is open-angle glaucoma despite pressure readings in the normal range. Lowering pressure can still slow damage. Do not dismiss documented optic nerve or visual-field loss because a pressure reading looks reassuring.
Distinguish chronic closure from an acute attack
Angle closure can develop slowly without symptoms. Sudden pain, redness, nausea or blurred vision needs emergency assessment, but absence of pain does not establish an open angle. Gonioscopy and specialist evaluation determine the mechanism and treatment.
Connect cupping to lost neural tissue
Glaucomatous optic neuropathy progressively injures retinal ganglion cell axons and remodels the optic nerve head. Increasing cup-to-disc appearance can support the diagnosis, but asymmetry, rim configuration, retinal nerve fiber imaging, and reproducible visual-field loss matter more than a single ratio.
Interpret tests in their clinical context
A large cup can accompany a large healthy disc, while a small cup does not exclude damage in a small disc. Examine the neuroretinal rim and compare structural findings with visual fields and the clinical examination. OCT alone does not establish glaucoma. Corneal thickness informs risk and pressure interpretation, but unvalidated thickness-based formulas should not be used to “correct” pressure.
Look for corticosteroid-associated pressure elevation
Medication review must include corticosteroids, especially ophthalmic preparations. Prolonged Pred Forte use can raise pressure in susceptible patients and cause glaucomatous nerve and field damage; it can also cause posterior subcapsular cataract and increase infection risk. Its label calls for routine pressure monitoring at ten days or longer and frequent checks in patients with glaucoma. This is not a ten-day guarantee of safety. Coordinate the anti-inflammatory and pressure-control plan with the eye clinician; do not stop necessary treatment prematurely or treat an unexplained red eye with leftover steroid drops.
Individualize target pressure
A target is a working range chosen from untreated pressure, damage severity, life expectancy, corneal and measurement context, risk factors, and rate of progression. Reassess it at follow-up, especially with confirmed progression. The rate of loss, remaining vision, life expectancy and treatment burden determine whether a lower target is needed.
Measure structure and function
Pressure fluctuates and does not directly report neuronal survival. Serial optic nerve examination, retinal nerve fiber imaging, visual fields, gonioscopy when indicated, and adherence assessment reveal whether treatment protects vision.
Quick check
Checking for saved practice…
Lesson
Prostaglandin Analogs and Related Agents
Latanoprost, travoprost, tafluprost, bimatoprost, and latanoprostene bunod lower pressure primarily by increasing outflow, with meaningful local and product-specific safety differences.
- FP receptor signaling
- Uveoscleral outflow
- Pigmentation and adnexal effects
- Inflammation, macular, and corneal risks
Once-daily product-specific use
Hyperemia and adnexal changes
Pigmentation and periorbital change
Risk assessment before selection
Increase outflow
Prostaglandin F pathway agents remodel extracellular matrix and increase uveoscleral outflow. Latanoprostene bunod also releases nitric oxide, which can influence trabecular outflow. The exact dose and storage instructions remain product specific.
Counsel about visible change
Iris pigmentation can increase gradually and may be permanent. Eyelash length, thickness, number, pigmentation, and direction can change, while eyelid skin and periorbital tissues may also change. Unilateral treatment can produce noticeable asymmetry.
Respect inflammation and retinal context
Use requires caution according to the product in patients with active intraocular inflammation, macular edema risk, or a history of herpetic keratitis. New pain, photophobia, vision decline, or marked redness requires prompt evaluation rather than automatic continuation.
Use the Xalatan regimen
Xalatan 0.005% is one drop in each affected eye every evening. Resume the normal schedule after a missed dose. Extra daily doses or another prostaglandin analog can reduce benefit or paradoxically increase pressure. Separate other topical ophthalmic drugs by at least five minutes; remove contacts and wait 15 minutes before reinsertion.
Track storage and ocular exclusions
Protect Xalatan from light and refrigerate unopened bottles at 2-8°C; an opened bottle may be kept at up to 25°C for six weeks. Avoid it in active herpes simplex keratitis and generally avoid use during active intraocular inflammation. A history of these conditions, aphakia, a torn posterior lens capsule after lens replacement, or other macular-edema risk requires careful review.
Handle Vyzulta as its own product
Vyzulta is latanoprostene bunod 0.024%: one drop in each affected eye every evening. Its metabolites support trabecular and uveoscleral outflow. Refrigerate unopened bottles at 2-8°C; after opening, store at 2-25°C for eight weeks. Protect from light and freezing. It contains benzalkonium chloride; remove lenses and wait 15 minutes before reinsertion. Separate other eye medicines by at least five minutes.
Distinguish Zioptan pouch storage from single-dose use
Zioptan is preservative-free tafluprost 0.0015%, one drop in each affected eye every evening. Refrigerate unopened pouches at 2-8°C. Under the April 2026 label, unopened units in an opened pouch may remain at 20-25°C for 30 days, protected from moisture; record the opening date. Once a unit is opened, use it immediately for the prescribed eye or eyes and discard the remainder. Separate other eye medicines by five minutes; remove lenses and wait 15 minutes before reinsertion.
Recognize that BAK-free does not mean preservative-free
Travatan Z contains travoprost 0.004% with the sofZia preservative system, rather than benzalkonium chloride. Use one drop in each affected eye every evening. Store at 2-25°C; its label permits use after opening until the bottle expiration date. It still requires lens removal with a 15-minute wait before reinsertion and at least five minutes between eye medicines. Assess individual tolerance rather than promising that changing preservatives will resolve all surface symptoms.
Keep Lumigan concentration and storage explicit
Lumigan 0.01% is bimatoprost, one drop in each affected eye every evening. Store at 2-25°C; the opened bottle can be used until its expiration date. It contains benzalkonium chloride: remove lenses, wait 15 minutes before reinsertion, and separate other eye medicines by five minutes. Hypersensitivity to its ingredients is a contraindication. Review inflammation and macular-edema risk; periorbital fat changes, pigmentation and eyelash effects can affect adherence.
Check the Xelpros formulation
Xelpros is latanoprost 0.005% emulsion, preserved with potassium sorbate rather than BAK. Use one drop each evening. Its current label permits storage at 2-25°C, protected from light, and use after opening until the stamped expiration date. Do not apply Xalatan’s refrigeration and six-week rule to this product. Remove lenses for 15 minutes and separate other eye medicines by five minutes.
Reconcile both Rocklatan ingredients
Rocklatan combines netarsudil 0.02% with latanoprost 0.005%, one drop each evening. Adding Rhopressa or Xalatan duplicates an ingredient; clarify the intended regimen. Refrigerate unopened bottles at 2-8°C. After opening, the limit is six weeks at 2-25°C, or the stamped expiration if kept refrigerated at 2-8°C. Protect from light; remove lenses for 15 minutes and separate drops by five minutes. Eye pain or decreased vision warrants prompt evaluation for possible epithelial corneal edema.
Include eyelash prescriptions in reconciliation
Latisse is bimatoprost 0.03% for eyelash hypotrichosis. Apply nightly to the upper eyelid margin with the supplied sterile applicators, using a fresh applicator for each eyelid and blotting runoff. It is not a substitute for prescribed glaucoma drops. A patient using a glaucoma prostaglandin should consult the physician before adding it and have pressure monitored: Latisse can interfere with pressure lowering. This is a labeled warning requiring supervision, rather than a formal contraindication to every combined use.
Interpret reproductive evidence without promising safety
Rocklatan lacks adequate human pregnancy studies; its label reserves use for situations where expected benefit justifies fetal risk. Lumigan and Latisse also require an individual benefit-risk decision despite reassuring bimatoprost postmarketing observations. Animal findings and low systemic exposure do not establish human safety. Their lactation labels describe uncertainty about human milk exposure and call for weighing breastfeeding benefits, maternal need and possible infant effects. Arrange ophthalmology and obstetric review rather than stopping sight-preserving therapy without a plan.
Keep eyelash treatment evidence separate
Rocklatan has no established pediatric safety or effectiveness. Latisse has limited pediatric eyelash-treatment study data, which do not establish a pediatric glaucoma indication or override Lumigan’s age restriction. For Latisse counseling, remove lenses and wait 15 minutes before reinsertion; store at 2-25°C. Skip a missed application and resume the next evening. Extra applications do not speed growth, and eyelash benefits gradually diminish after stopping.
Do not apply one pediatric cutoff to the entire class
The reviewed labels do not recommend Zioptan in pediatric patients, Vyzulta in those aged 16 years or younger, and Travatan Z or Lumigan below age 16. These are product-specific labeling limits, not evidence that another glaucoma product is automatically appropriate for a child. Pediatric treatment requires specialist selection.
Quick check
Checking for saved practice…
Lesson
Beta Blockers, Alpha-2 Agonists, and Carbonic Anhydrase Inhibitors
Topical products can reach systemic circulation. Timolol, brimonidine, dorzolamide, and brinzolamide therefore require whole-patient medication and disease review.
- Ophthalmic beta blockade
- Alpha-2 agonism
- Topical carbonic anhydrase inhibition
- Systemic absorption
Systemic heart and airway effects
Less secretion + more uveoscleral flow
Sulfonamide and corneal considerations
Reduce nasolacrimal systemic exposure
Treat beta-1 selectivity as relative protection
Betaxolol is beta-1 selective, but pulmonary reactions remain possible. Betoptic S requires caution in impaired lung function; asthma attacks and respiratory distress have been reported. It is contraindicated with sinus bradycardia, greater-than-first-degree AV block, overt cardiac failure, cardiogenic shock or ingredient hypersensitivity. Review systemic beta blockers and other heart-rate-lowering drugs. Selectivity does not eliminate systemic absorption or cardiac risk.
Use the Betoptic S suspension correctly
Betoptic S 0.25% supplies one drop twice daily after shaking well. Give other topical eye medicines at least ten minutes before it. Remove contacts and wait 15 minutes before reinsertion. Store upright at 2-25°C; opened bottles can be used until their expiration date. Do not infer the 0.5% solution’s instructions from this suspension’s concentration or name.
Check the betaxolol solution separately
The Sandoz 0.5% solution label specifies one or two drops in each affected eye twice daily and storage at 20-25°C. It contains BAK. Its concentration, dose range and storage differ from Betoptic S suspension. Pediatric safety and effectiveness are not established for this solution; do not transfer the suspension’s pediatric evidence to it.
Do not confuse intrinsic activity with airway safety
Carteolol 1% is a nonselective beta blocker with intrinsic sympathomimetic activity. Its dose is one drop twice daily; store at 15-25°C, protected from light. Asthma or its history, severe COPD, sinus bradycardia, second- or third-degree AV block, overt cardiac failure and cardiogenic shock remain contraindications. Intrinsic activity does not remove systemic beta-blocker risk.
Check levobunolol dose and sulfite sensitivity
The Bausch + Lomb 0.5% solution starts at one or two drops once daily; severe or uncontrolled disease may require twice-daily treatment. Above one drop twice daily generally adds no benefit. It contains sodium metabisulfite, which can provoke allergic or asthmatic reactions. Apply its nonselective beta-blocker contraindications and avoid duplicate topical beta blockers. Store at 15-25°C, protected from light, and recap immediately.
Reconcile levobunolol precautions
Remove soft contacts before levobunolol and wait at least 15 minutes before reinsertion. Review oral beta blockers, calcium-channel blockers, digoxin, reserpine and phenothiazines for additive cardiovascular effects. Reduced cerebral perfusion symptoms require reassessment. Pediatric safety is unestablished; pregnancy requires an individual benefit-risk decision, and nursing warrants caution. Low topical doses do not establish safety for every patient.
Use timolol with systemic beta-blocker caution
Timolol reduces aqueous production through nonselective beta blockade. Ophthalmic exposure can cause bradycardia, heart block, heart failure worsening, hypotension, bronchospasm, and reduced beta-2 rescue response. Asthma and specified conduction or cardiac conditions are major label constraints.
Use solution-specific timolol dosing
For the Sandoz 0.25%/0.5% solution, the usual starting regimen is one drop of 0.25% twice daily; inadequate response may warrant 0.5% twice daily. Reassess pressure after about four weeks. Once-daily treatment may be considered after satisfactory control, checking pressure at different times of day. More than one drop of 0.5% twice daily generally adds no benefit.
Check the actual timolol dispenser
This Sandoz bottle instructs one shake before use and pressure on the bottle bottom, not squeezing the sides. Separate other eye medicines by at least ten minutes before or after; remove soft contacts and wait 15 minutes. Store upright at 15-30°C, protected from light and freezing; opened bottles remain usable until their expiration date. These instructions belong to this dispenser, not every timolol solution.
Identify the once-daily timolol solution
The Bausch + Lomb 0.5% once-daily solution uses one drop each morning. Separate other eye medicines by five minutes; remove contacts and wait 15 minutes. It contains BAK and potassium sorbate. Store at 15-25°C; an opened bottle may be used until its expiration date. Pediatric safety and effectiveness are not established for this product. Confirm the dispensed formulation before changing a twice-daily prescription.
Handle preservative-free timolol vials correctly
Ingenus single-dose timolol starts at one drop of 0.25% twice daily, with possible escalation to 0.5% twice daily. Assess pressure after about four weeks; once-daily maintenance requires satisfactory control and checks at different times of day. Use an opened vial immediately for the prescribed eye or eyes, then discard any remainder. Keep unused vials in their foil overwrap at 15-30°C, protected from light and freezing; use within one month of opening the pouch. Preservative removal does not remove systemic beta-blocker contraindications.
Match timolol instructions to the formulation
Timoptic-XE is a gel-forming solution: one drop of the prescribed 0.25% or 0.5% strength in each affected eye once daily. Invert the closed bottle and shake once. Give other topical eye medicines at least ten minutes before it. Temporary blur can affect driving. Do not transfer these directions to every timolol product; check the exact formulation.
Screen beyond the eye before beta blockade
Timoptic-XE is contraindicated with asthma or its history, severe COPD, sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock, or product hypersensitivity. Review oral beta blockers, rate-slowing calcium-channel blockers, digoxin and CYP2D6 inhibitors for additive effects. Beta blockade may mask hypoglycemia symptoms, worsen myasthenic weakness, and reduce responsiveness to usual epinephrine doses during anaphylaxis. Punctal occlusion does not override these restrictions.
Use brimonidine with age and CNS caution
Brimonidine is an alpha-2 agonist that lowers production and may increase uveoscleral outflow. Fatigue, somnolence, dry mouth, allergy, and hypotension can occur. It is contraindicated in children younger than two years, and young children can have profound CNS depression.
Use the prescription brimonidine formulation
Alphagan P 0.1% or 0.15% is one drop in each affected eye three times daily, about eight hours apart, with other ophthalmic products separated by at least five minutes. Its label contraindicates use below age two; caution still applies in older children because sedation can be substantial. Review CNS depressants, antihypertensives, cardiac glycosides, tricyclic antidepressants and MAO inhibitors. The current label does not recommend use during lactation because of possible infant CNS depression and apnea.
Separate the peri-laser apraclonidine product
Iopidine 1% controls pressure spikes after specified anterior-segment laser procedures. Give one drop in the operative eye one hour before laser and another immediately afterward, using a fresh single-dose container each time and discarding it after use. Store at 2-25°C, protected from light. The US product contains BAK despite single-dose packaging; do not assume preservative-free.
Keep procedural alpha-agonist precautions visible
Iopidine 1% is contraindicated with MAO inhibitors or hypersensitivity to its ingredients or clonidine. Review severe cardiovascular disease and renal failure. Dizziness and somnolence can impair alertness. Pediatric safety is unestablished; serious cardiopulmonary collapse has been reported at age six and younger. The label calls for clinical monitoring and temporary breastfeeding interruption on the treatment day.
Keep apraclonidine within its short-term role
Apraclonidine 0.5% supplies additional pressure reduction when maximally tolerated therapy is insufficient. Its labeled dose is one or two drops in each affected eye three times daily, separated from other eye medicines by about five minutes. Benefit for most patients lasts less than a month as tolerance develops. Follow pressure closely; a significant rise or allergic ocular reaction requires stopping treatment and reassessment. MAO inhibitors and hypersensitivity to apraclonidine, its components, or systemic clonidine are contraindications. Do not treat it as an indefinitely effective maintenance drop.
Do not substitute redness relief for pressure treatment
Lumify contains brimonidine tartrate 0.025% for redness from minor irritation. It is not a replacement for prescribed glaucoma therapy. Matching the ingredient name is insufficient: indication, concentration, directions and patient restrictions belong to the specific product.
Give Azopt its own administration instructions
Azopt is brinzolamide 1% suspension: shake well and instill one drop in each affected eye three times daily. Separate other eye medicines by at least ten minutes. Remove contact lenses and wait 15 minutes before reinsertion. Store at 4-30°C; after opening, use until the bottle expiration. Wait until vision is clear before driving.
Review brinzolamide beyond the eye
Azopt is not recommended with creatinine clearance below 30 mL/min or concurrent oral carbonic anhydrase inhibitors. Review high-dose salicylates and acid-base risk. Low corneal endothelial counts increase edema risk. Serious hypersensitivity requires stopping the product and immediate medical advice; topical administration does not eliminate systemic sulfonamide reactions.
Match oral acetazolamide dosing to the formulation
For chronic open-angle glaucoma, the tablet label describes 250-1,000 mg per day, dividing amounts above 250 mg. The extended-release regimen is 500 mg twice daily. Doses above 1,000 mg daily generally add no benefit in this setting. Acute preoperative regimens differ and require specialist supervision; these are not instructions for self-treating a painful eye.
Clarify the reported sulfonamide reaction
Record the culprit drug, reaction, timing and severity. The 2022 drug-allergy practice parameter finds little concern for cross-reactivity between sulfonamide antibiotics and nonantimicrobial carbonic anhydrase inhibitors. A vague “sulfa allergy” is not proof of acetazolamide allergy. Its label still contraindicates hypersensitivity to acetazolamide or its excipients and warns about possible cross-sensitivity and severe reactions. Reconcile a serious reaction history with the prescriber or allergy specialist; do not erase the allergy or guarantee tolerance.
Screen before systemic carbonic anhydrase inhibition
Acetazolamide is contraindicated with low sodium or potassium, marked kidney or liver dysfunction, adrenal failure, hyperchloremic acidosis, and cirrhosis. Check CBC and platelets before treatment and periodically, along with electrolytes. Paresthesia, fatigue, altered taste, polyuria, stones and metabolic acidosis can limit use. Serious rash or hypersensitivity requires discontinuation and prompt care.
Reconcile oral therapy and new visual symptoms
High-dose aspirin with acetazolamide has caused severe toxicity, including acidosis, coma and death. Review other carbonic anhydrase inhibitors, lithium, phenytoin, primidone, cyclosporine and sodium bicarbonate. After eye surgery, suspected choroidal effusion or detachment requires acetazolamide discontinuation and urgent ophthalmic assessment. A pressure-lowering drug can itself contribute to an ocular adverse reaction.
Distinguish methazolamide from acetazolamide
Methazolamide’s labeled dose is 50-100 mg two or three times daily. Less renal clearance does not make it appropriate in marked kidney disease; renal, hepatic, electrolyte, adrenal and acidosis restrictions still apply. Obtain baseline and periodic CBC, platelets and electrolytes. Review high-dose aspirin and steroid-associated hypokalemia. Long-term treatment of angle closure is contraindicated because reduced pressure can mask continued angle obstruction.
Reconcile breastfeeding advice by drug and infant
LactMed reports low milk exposure with maternal acetazolamide doses up to 1,000 mg/day and considers adverse infant effects unlikely at those doses. This differs from the more cautious nursing language in product labeling. Review the infant’s age, prematurity and clinical condition with the treating team; reports of neonatal acidosis after pregnancy exposure do not by themselves prove toxicity from breast milk. Do not generalize these limited observations to every dose or every carbonic anhydrase inhibitor.
Do not transfer timolol advice to brimonidine combinations
LactMed considers ophthalmic timolol a generally low exposure during breastfeeding but notes variable milk transfer and limited experience; alternatives may be preferred for newborn or premature infants. Punctal pressure for at least one minute and wiping away excess drops reduce exposure. A timolol-only assessment does not resolve the brimonidine risk in Combigan. Current brimonidine labeling discourages lactation use because of potential infant CNS depression and apnea; a few uneventful case reports do not establish safety.
Verify renal dosing rather than copying the usual schedule
Acetazolamide’s U.S. label contraindicates marked renal dysfunction without giving a numerical adjustment table. A January 2026 Vancouver Coastal Health adult IV protocol uses 125-250 mg every 12 hours for creatinine clearance 10-50 mL/min in acute glaucoma and still excludes severe renal impairment. That institutional IV schedule is not a universal oral or extended-release regimen. Confirm formulation, renal function, acid-base status and the applicable specialist protocol; a dose reduction does not cancel a contraindication.
Use topical carbonic anhydrase inhibitors as sulfonamides
Dorzolamide and brinzolamide inhibit ciliary carbonic anhydrase and reduce bicarbonate-dependent fluid secretion. Topical delivery does not prevent systemic absorption. Review severe sulfonamide reactions, corneal endothelial risk, kidney context, and concurrent oral carbonic anhydrase inhibition.
Apply dorzolamide-specific renal and corneal limits
Dorzolamide 2% alone is one drop in each affected eye three times daily. Its label does not recommend use when creatinine clearance is below 30 mL/min because the drug and metabolite depend on renal elimination. Concurrent oral carbonic anhydrase inhibition is also not recommended. Low corneal endothelial cell counts increase edema risk. Severe hypersensitivity or allergic eye or lid reactions require discontinuation and clinical evaluation; topical delivery does not remove systemic sulfonamide risk.
Reduce nasolacrimal exposure
After a drop, gently closing the eyelid and applying punctal pressure can reduce drainage into the nose and systemic absorption. This technique lowers but does not eliminate systemic risk. One properly placed drop is generally enough for the conjunctival sac.
Quick check
Checking for saved practice…
Lesson
Rho Kinase, Cholinergic, Laser, and Surgical Outflow
Trabecular outflow can be changed pharmacologically, with laser, or by creating new drainage pathways. The choice depends on mechanism, progression, burden, and anatomy.
- Rho kinase inhibition
- Pilocarpine and miosis
- Selective laser trabeculoplasty
- Incisional and minimally invasive procedures
Trabecular outflow and hyperemia
Meshwork tension with miosis
Posterior to anterior chamber route
Initial or later care, based on risk
Relax trabecular resistance
Netarsudil inhibits Rho kinase; its label describes increased trabecular outflow as the presumed pressure-lowering mechanism. Hyperemia, corneal verticillata, instillation pain, and conjunctival hemorrhage are common local effects. New pain or reduced vision requires prompt ophthalmic advice: epithelial corneal edema has been reported, particularly with pre-existing stromal edema or procedures affecting endothelial function.
Distinguish established labeling from mechanistic research
A seven-day, paired-eye study in 11 healthy volunteers found increased trabecular outflow facility with netarsudil. Episcleral venous pressure fell from baseline in treated eyes, but its difference from vehicle-treated eyes was not statistically significant; reduced aqueous production was also only a nonsignificant trend. These findings help explain possible additional mechanisms without establishing three equally proven effects in patients with glaucoma.
Use the Rhopressa schedule and storage conditions
Rhopressa 0.02% is dosed as one drop in each affected eye every evening. Resume at the next evening dose after a missed dose; twice-daily dosing is not recommended. Refrigerate unopened bottles at 2-8°C. After opening, storage at 2-25°C permits up to six weeks; the current label permits use until the stamped expiration if kept refrigerated at 2-8°C. Verify the actual bottle label and storage history rather than extending a room-temperature bottle by refrigerating it later.
Use pilocarpine by mechanism
Muscarinic M3 activation contracts ciliary muscle and can open trabecular spaces while producing miosis and accommodative spasm. Headache, brow ache, reduced night vision, retinal concerns, and systemic cholinergic effects limit broad chronic use.
Apply pilocarpine product precautions
For open-angle pressure control, Somerset pilocarpine 1%, 2% or 4% is one drop up to four times daily; begin treatment-naïve patients at 1%. Obtain a retinal examination before treatment. Avoid use with iritis. Do not drive with unclear vision. This product specifies two-minute punctal occlusion, five-minute drug separation and ten-minute contact-lens reinsertion. Store at 15-25°C without freezing.
Separate surgical carbachol from home eye drops
Miostat is carbachol 0.01% for intraocular administration during surgery to produce miosis; it also reduces early pressure elevation after cataract surgery. It is not a take-home multidose glaucoma drop. A prescription giving Miostat a routine topical drop schedule requires clarification of the intended product and route before dispensing. Shared cholinergic pharmacology does not make surgical and topical formulations interchangeable.
Relieve pupillary block definitively
In acute primary angle closure caused by pupillary block, pressure-lowering medicines stabilize the eye and improve the ability to perform definitive treatment. Laser peripheral iridotomy creates another route from the posterior to the anterior chamber and relieves the block. Persistent closure after a patent iridotomy requires reassessment for plateau iris, synechiae, lens, or another nonpupillary mechanism.
Use laser as treatment, not failure
Selective laser trabeculoplasty targets pigmented trabecular cells and can be initial or adjunctive therapy in appropriate open-angle disease. Effect may diminish, repeatability and anatomy vary, and early pressure response still requires monitoring.
Plan follow-up after laser
After iridotomy, confirm that the opening is patent and reassess the angle; residual closure can have another mechanism. EGS guidance calls for pressure assessment one to three hours after iridotomy or trabeculoplasty. After trabeculoplasty, high-risk eyes need additional early follow-up, while treatment efficacy is assessed later, around six to eight weeks. Laser does not end surveillance.
Create a new pathway when needed
Trabeculectomy, drainage devices, and minimally invasive glaucoma procedures alter outflow through different routes and risk profiles. Surgery becomes appropriate when the probability of vision loss exceeds the burden and risk of intervention. Advanced visual-field loss at presentation can justify initial surgery; exhausting every drop first is not mandatory. Minimally invasive procedures are not interchangeable with filtration surgery for rapidly progressing disease.
Quick check
Checking for saved practice…
Lesson
Acute Angle Closure and Medication Triggers
Acute angle closure threatens vision. Identify the cause while arranging immediate ophthalmic care; pupillary block and drug-induced effusion require different treatment.
- Emergency recognition
- Pupillary block
- Topiramate-associated effusion
- Supervised medication withdrawal
Immediate eye assessment
Iridotomy bypasses the block
Miotics may worsen closure
Review and withdraw the trigger
Recognize the emergency
Sudden blurred vision, halos, eye pain, redness, headache or nausea can signal acute angle closure. Arrange immediate ophthalmic evaluation; use emergency services when timely specialist care is unavailable. Do not trial redness drops or wait for routine follow-up.
Ask which mechanism closed the angle
Anticholinergic or sympathomimetic exposure can precipitate pupillary block in susceptible narrow angles. Pressure-lowering therapy stabilizes the acute attack; iridotomy treats the pupillary block. A previous iridotomy does not exclude another mechanism. Review prescription, nonprescription and recently changed medicines.
Lower pressure while preparing definitive care
In a specialist-managed acute attack, begin aqueous suppressants selected for the patient’s contraindications; prostaglandins act more slowly. EGS recommends immediate acetazolamide when pressure is at least 40 mmHg, with intravenous treatment when rapid onset is needed or vomiting prevents oral treatment. Review renal function, electrolytes, acidosis and hypersensitivity before systemic therapy. Treat inflammation with topical corticosteroid under ophthalmic supervision.
Verify the acute acetazolamide order
The Hikma injection label describes 250 mg every four hours for some acute preoperative cases, or an initial 500 mg followed by 125-250 mg every four hours, individualized by the treating clinician. EGS instead specifies 10 mg/kg intravenously when rapid treatment is needed. Keep the selected regimen, renal assessment and monitoring explicit; do not add a weight-based loading dose to a fixed-dose schedule without an order.
Separate solution stability from the use deadline
Hikma’s 500-mg injection vial requires at least 5 mL of sterile water for injection; direct intravenous administration is preferred and intramuscular administration is not recommended. Although its preparation section describes longer refrigerated physical/chemical stability, the supply instructions require refrigeration and use within 12 hours of reconstitution. Follow the product’s use deadline and applicable sterile-preparation policy; discard unused solution.
Time pilocarpine to the mechanism and pressure
For suspected pupillary block, EGS uses pilocarpine 2%, but defers it until pressure falls when the presenting pressure is at least 40 mmHg: an ischemic iris may not respond. Avoid intensive repeated dosing. Lens-induced or retrolenticular closure requires cycloplegia instead; miotics can worsen it.
Screen before hyperosmotic treatment
Mannitol may be considered after an inadequate response to initial treatment. Its label contraindicates use with anuria, severe hypovolemia, pulmonary vascular congestion or edema, active intracranial bleeding except during craniotomy, or hypersensitivity. Assess renal, cardiac, pulmonary and fluid status; monitor electrolytes and osmolality. Inspect for crystals and use an in-line filter according to the product instructions.
Verify the ordered mannitol regimen
The reviewed ICU Medical 20% mannitol label gives 1.5-2 g/kg intravenously over at least 30 minutes for lowering intraocular pressure. EGS describes a lower 0.5-1.5 g/kg range for acute angle closure. These are different source regimens: confirm the specialist order, concentration and institutional protocol rather than combining their dose and rate instructions. Mannitol can cause fluid overload or kidney injury, so repeated dosing is not automatic.
Convert the ordered dose before selecting volume
Worked example: a specialist orders a single mannitol dose of 1.5 g/kg for a 60-kg adult after assessing contraindications. The dose is 90 g. A 20% solution contains 20 g per 100 mL, or 0.2 g/mL, so the required volume is 90 ÷ 0.2 = 450 mL. This calculation does not establish that the patient can tolerate that fluid volume; verify the infusion order and monitoring plan separately.
Complete definitive treatment and assess the other eye
For pupillary block, perform laser peripheral iridotomy once the cornea permits it. Persistent edema or inadequate pressure response may require another specialist procedure. Assess the fellow eye promptly; EGS recommends prophylactic iridotomy in the phakic fellow eye in this setting before discharge. Recheck the angle and pressure after the attack.
Recognize the topiramate pattern
Topiramate can cause effusion with forward displacement of the lens and iris, acute myopia and secondary angle closure. Children as well as adults are affected, often within the first month. New visual symptoms require immediate medical attention even without prior glaucoma. The treating clinician should discontinue topiramate rapidly when this syndrome is suspected, with monitoring when rapid withdrawal is medically required.
Avoid treating effusion as pupillary block
For confirmed topiramate-associated effusion, specialist treatment includes pressure reduction, cycloplegia and anti-inflammatory therapy. Miotics such as pilocarpine can worsen forward displacement; iridotomy does not correct a pure nonpupillary mechanism. Diagnostic uncertainty requires specialist judgment, not an automatic procedure. Coordinate alternative systemic treatment with the prescriber.
Quick check
Checking for saved practice…
Lesson
Selection, Combination, and Progression Monitoring
The best regimen reaches an individualized pressure target, slows progression, fits systemic disease, minimizes local toxicity, and can actually be administered over years.
- Target pressure
- Class selection
- Combination and duplication
- Adherence and escalation
Baseline damage and rate
Structure and function over time
Comorbidity and adherence
Rate of loss and lifetime visual risk
Plan glaucoma care before and during pregnancy
Discuss pregnancy plans early with ophthalmology and obstetrics. Consider whether laser or surgery could reduce medication needs, while weighing each procedure’s risks and suitability. Pressure may fall during pregnancy, but glaucoma can still progress; treatment reduction requires close pressure and visual-field follow-up. If medicine is needed, use the lowest effective regimen and reduce nasolacrimal absorption. Balance fetal concerns against the mother’s risk of permanent visual loss.
Distinguish pregnancy evidence from a safety ranking
Do not select a glaucoma drug solely from an old pregnancy letter category. Current Alphagan P labeling describes insufficient human evidence and requires a benefit-risk decision; EGS advises avoiding brimonidine in late pregnancy because of potential neonatal apnea. Beta blockers have more clinical experience, but newborn cardiac and respiratory effects remain concerns. An observational study finding no statistically significant excess low birth weight with topical beta blockers does not prove absence of all fetal risks. Prostaglandin and carbonic anhydrase inhibitor animal findings likewise do not establish a precise human risk.
Choose a mechanism that fits the patient
Prostaglandin pathway therapy often offers strong once-daily pressure reduction, but ocular history and visible changes matter. Beta blockers may be unsuitable in airway or conduction disease. Alpha-2 agonists and carbonic anhydrase inhibitors have age, allergy, kidney, corneal, and adherence considerations.
Discuss laser at the initial decision
NICE NG81 recommends offering 360° selective laser trabeculoplasty for newly diagnosed nonadvanced chronic open-angle glaucoma, excluding pigment-dispersion-associated cases. Explain that drops may still be needed and laser benefit can diminish. When laser is unsuitable, declined, or awaiting treatment, a generic prostaglandin analog has a role.
Recognize advanced disease at presentation
NICE recommends offering glaucoma surgery, with mitomycin C augmentation as indicated, for advanced chronic open-angle glaucoma. Discuss benefits and risks; a generic prostaglandin can provide interim treatment while awaiting surgery. Treatment selection requires ophthalmic assessment and patient preferences, rather than an automatic sequence of additional bottles.
Avoid silent ingredient duplication
Fixed-combination drops reduce bottle burden but can hide duplicate timolol, brimonidine, or carbonic anhydrase inhibitor exposure when another product is added. Reconcile active ingredients rather than brand names or cap colors.
Read the ingredients inside a combination
Cosopt PF combines dorzolamide 2% with timolol 0.5% and is one drop in each affected eye twice daily. Combigan combines brimonidine tartrate 0.2% with timolol 0.5%, also one drop twice daily, about twelve hours apart. Using these together duplicates timolol. Both retain important beta-blocker pulmonary and cardiac contraindications; removing preservatives does not remove timolol’s systemic effects.
Recognize the combination without a beta blocker
Simbrinza contains brinzolamide 1% plus brimonidine tartrate 0.2%, with no timolol. Shake the suspension well and use one drop in each affected eye three times daily. Separate other ophthalmic products by at least five minutes. Absence of timolol does not make it suitable for everyone: it is contraindicated below age two and not recommended with creatinine clearance below 30 mL/min. Review hypersensitivity, corneal endothelial health, sedation and vascular risk.
Balance fewer bottles against the actual regimen
The combination’s labeled schedule is its own regimen. Do not copy standalone dorzolamide’s three-times-daily directions onto Cosopt PF or standalone brimonidine’s schedule onto Combigan. Their labels report slightly less pressure lowering than the corresponding separately administered components at the compared schedules. Check the response after switching. Open a Cosopt PF unit only when ready to administer it, use it immediately for the prescribed eye or eyes, and discard the remaining solution; do not save it for the next dose.
Check both components for interactions
Cosopt PF and Simbrinza are not recommended with oral carbonic anhydrase inhibitors; assess high-dose salicylate exposure because acid-base and electrolyte interactions are possible. Timolol-containing combinations require review of systemic beta blockers, calcium-channel blockers, digoxin and CYP2D6 inhibitors for additive cardiovascular effects. Brimonidine combinations require caution with CNS depressants, antihypertensives, tricyclic antidepressants and MAO inhibitors; distinguish a label precaution from a formal contraindication.
Keep combination precautions patient-specific
Cosopt PF is not recommended when creatinine clearance is below 30 mL/min; use caution with hepatic impairment or low corneal endothelial cell counts. Serious hypersensitivity requires discontinuation and urgent assessment. Combigan is contraindicated below age two; older children still need monitoring for sleepiness and reduced alertness. Its March 2026 label does not recommend use during lactation because of potential infant CNS depression and apnea.
Distinguish the preserved Cosopt bottle
Preserved Cosopt has the same dorzolamide 2%/timolol 0.5% strengths and twice-daily one-drop regimen, but contains BAK 0.0075%. For the reviewed Théa bottle, separate other eye drops by at least five minutes, remove soft contacts and wait 15 minutes before reinsertion. Store at 20-25°C protected from light; after opening, use through the labeled expiration date. Do not apply Cosopt PF’s 15-day pouch limit to this multidose bottle. Both formulations retain the renal, corneal, pulmonary, cardiac and interaction precautions of their active ingredients.
Date the Cosopt PF pouch
Store Cosopt PF at 20-25°C without freezing. Keep unused vials inside the original foil pouch to protect them from light, record the opening date, and discard remaining vials 15 days later. This pouch limit is separate from the immediate disposal of each opened vial. Space other ophthalmic medicines by at least five minutes.
Store Combigan as its own product
Keep Combigan at 15-25°C, protected from light, and replace the cap after use. Do not use beyond the labeled expiration date or if its appearance changes. It contains BAK: remove soft contacts and wait 15 minutes before reinsertion. Drowsiness can impair driving and other activities requiring alertness.
Finish Simbrinza counseling
Store Simbrinza at 2-25°C; an opened bottle can be used until its labeled expiration date. Remove contacts before dosing and wait 15 minutes before reinsertion. Warn about temporary blur and drowsiness. Serious skin or other hypersensitivity reactions require stopping the product and prompt medical assessment. Its lactation label calls for a decision between discontinuing nursing or the drug; assess the infant risk from brimonidine rather than assuming that a beta-blocker-free combination is safe.
Interpret apparent failure
Before adding therapy, verify diagnosis, target, technique, timing relative to pressure measurement, missed doses, bottle access, contamination, storage, preservative intolerance, and whether the medicine reaches the eye.
Escalate to protect vision
If confirmed progression continues, reassess the target against rate of loss and lifetime visual risk. When more pressure reduction is needed, consider another mechanism, laser, or surgery according to angle anatomy and risk. A comfortable pressure number does not justify delay when structural or functional loss is documented.
Quick check
Checking for saved practice…
Lesson
Ophthalmic Administration and Safety
Technique determines delivered dose, contamination risk, washout, adherence, and systemic spillover. Device ability is part of prescribing.
- Prescribed drop dose
- Tip contamination
- Punctal occlusion
- Contact lenses and product separation
Avoid tip contamination
Avoid unprescribed extra drops
Reduce nasolacrimal absorption
Prevent washout and dosing error
Deliver the prescribed drop dose
Wash hands, tilt the head, and create a lower-lid pocket. Instill the prescribed number of drops without touching the tip to the eye, lashes, skin, or fingers. Most regimens here use one drop, but some labels specify one or two. Do not add extra drops to compensate for concern about efficacy; excess volume increases spillover and drainage.
Do not assume every eye drop is 0.05 mL
Drop volume depends on the formulation and dispenser. Xalatan lists 50 mcg/mL and approximately 1.5 mcg per drop: 1.5 mcg ÷ 50 mcg/mL gives approximately 0.03 mL per drop. A 0.05 mL assumption would instead imply 2.5 mcg and misstate this product’s approximate delivered dose. Use product-specific information for calculations; actual bottle duration also depends on technique and waste.
Close and occlude
Close the eyelid gently without squeezing and apply pressure near the inner canthus for the product-recommended interval. This reduces nasolacrimal drainage. Blinking forcefully can pump medicine toward the nose.
Separate products and contact lenses
When multiple ophthalmic products are used, separate them according to label instructions to reduce washout. Ointments generally follow drops. Remove and reinsert contact lenses according to the product's preservative and timing instructions.
Solve physical and cognitive barriers
Tremor, arthritis, poor vision, weakness, cognition, bottle stiffness, and complex schedules can prevent accurate use. Observe technique, simplify where possible, add an appropriate device or caregiver, and verify refill access.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 139 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Pred Forte prescribing information (02/2024)
- Ho et al. Antiglaucoma medications during pregnancy and low birth weight (2009)
- Brauner et al. Course of glaucoma during pregnancy (2006)
- LactMed. Acetazolamide (2025)
- LactMed. Timolol (2026)
- LactMed. Brimonidine (2026)
- Vancouver Coastal Health. Adult parenteral acetazolamide (2026)
- Drug allergy: 2022 practice parameter update
- DailyMed. Hikma acetazolamide injection prescribing information
- DailyMed. Théa preserved Cosopt prescribing information
- DailyMed. ICU Medical mannitol 20% injection prescribing information
- DailyMed. Bausch + Lomb once-daily timolol solution prescribing information
- DailyMed. Ingenus preservative-free timolol prescribing information
- DailyMed. Betaxolol 0.5% solution prescribing information
- DailyMed. Carteolol 1% prescribing information
- DailyMed. Levobunolol 0.5% prescribing information
- European Glaucoma Society. Guidelines, sixth edition (2025)
- DailyMed. Sandoz timolol solution prescribing information
- DailyMed. Betoptic S prescribing information
- DailyMed. Iopidine 1% prescribing information (03/2026)
- DailyMed. Acetazolamide tablets
- DailyMed. Acetazolamide extended-release capsules
- DailyMed. Methazolamide tablets
- DailyMed. Azopt prescribing information (11/2023)
- NICE NG81. Glaucoma diagnosis and management: recommendations
- NICE. Management options for chronic open-angle glaucoma (2022 visual summary)
- DailyMed. Xelpros prescribing information
- DailyMed. Rocklatan prescribing information
- DailyMed. Latisse prescribing information
- DailyMed. Vyzulta prescribing information
- DailyMed. Zioptan prescribing information
- DailyMed. Travatan Z prescribing information
- DailyMed. Lumigan 0.01% prescribing information
- DailyMed. Topamax prescribing information: ocular warnings and withdrawal (03/2026)
- University of Iowa EyeRounds. Topiramate-induced angle closure (2019)
- DailyMed. Somerset pilocarpine 1%, 2%, 4% prescribing information (12/2025)
- DailyMed. Cosopt PF prescribing information
- DailyMed. Combigan prescribing information
- DailyMed. Simbrinza prescribing information
- DailyMed. Alphagan P prescribing information
- DailyMed. Apraclonidine 0.5% (Sandoz) prescribing information
- DailyMed. Lumify 0.025% Drug Facts
- DailyMed. Timoptic-XE gel-forming solution: prescribing information and instructions
- Kazemi et al. Netarsudil and aqueous humor dynamics: randomized study in healthy volunteers (2018)
- DailyMed. Miostat (carbachol 0.01%) intraocular solution: route and surgical indication
- DailyMed. Xalatan (latanoprost 0.005%) prescribing information
- DailyMed. Dorzolamide hydrochloride ophthalmic solution
- DailyMed. Netarsudil ophthalmic solution
- National Eye Institute. Types of glaucoma